Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Provided By PR Newswire

Last update: Nov 9, 2023

PALO ALTO, Calif., Nov. 9, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.